Natural Capsules credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
114114104
11011098.5
0.49×0.49×0.40×
0.47×0.47×0.38×
−73.31×−73.31×5.93×
−144.26×−70.22×5.62×
−1.71×−1.71×1.33×
32.8%32.8%28.8%
As filed — company-reported covenants
——40.00×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NATCAPSUQ₹137.93

Natural Capsules Limited

· Pharma & Health
₹ CrorePeersNECLIFEAAREYDRUGSBALPHARMAALPAKREBSBIOMEDICAMEQMEDICOVINEETLABMcap ₹143 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt103.8114.3114.3
Net Debt98.5109.5109.5
Total Debt/Equity0.400.490.49
Net Debt/Equity0.380.470.47
Total Debt/EBITDA5.93-73.31-73.31
Net Debt/EBITDA5.62-70.22-144.26
Interest Coverage (EBIT/Interest)1.33-1.71-1.71
Total Debt/Total Capital %28.7632.7632.76
As Filed — company-reported covenants
Debt/Equity (as filed)40.00——
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.